Page 3 - Cardiovascular Risk Reduction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl)

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl)
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesUnited arab emiratesNew jerseyGreat britainMark marmurColl cardiolClin cardiolAmerican heart associationAmarin corporationEuropean unionA report from the american heart associationDrug administrationExchange commissionAlso foundTotal events compared

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative

Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo

United kingdomUnited statesNew jerseyUnited arab emiratesGreat britainMark marmurClin cardiolColl cardiolA report from the american heart associationEuropean unionDrug administrationAmerican heart associationAmarin corporationExchange commissionAlso foundTotal events compared

Amarin Corporation plc: Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

Amarin Corporation plc: Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Noord hollandUnited statesUnited arab emiratesNew jerseyGabriel stegColl cardiolPascalm burgerJohnr nelsonMichael millerHandrean sorenNabil abadirPeterp tothMark marmurJannickan dorresteijnDeepakl bhattClin cardiol

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 Amarin Corporation plc today announced the acceptance of funded research for presentation at the European Society of Cardiology Congress,.

New jerseyUnited statesUnited arab emiratesNoord hollandPascalm burgerGabriel stegColl cardiolHandrean sorenJohnr nelsonMichael millerPeterp tothNabil abadirJannickan dorresteijnDeepakl bhattMark marmurClin cardiol

Amarin Corporation plc: Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

- New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression - Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism

United statesLoyola universityNew jerseyUnited arab emiratesMark marmurColl cardiolMarkg rabbatMohamad kassabNabil abadirClin cardiolLisa defrancescoFarouc jafferAmarin pharmaceuticals irelandJournal of the american college cardiologyAmerican heart associationExchange commission